These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 17605513)

  • 1. Telithromycin: the perils of hasty adoption and persistence of off-label prescribing.
    Gleason PP; Walters C; Heaton AH; Schafer JA
    J Manag Care Pharm; 2007 Jun; 13(5):420-5. PubMed ID: 17605513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limit Ketek to pneumonia, experts advise: advisers urge black-box warning.
    Young D
    Am J Health Syst Pharm; 2007 Jan; 64(2):124-5. PubMed ID: 17215452
    [No Abstract]   [Full Text] [Related]  

  • 3. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events.
    Starner CI; Schafer JA; Heaton AH; Gleason PP
    J Manag Care Pharm; 2008; 14(6):523-31. PubMed ID: 18693776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telithromycin. Aventis Pharma.
    Johnson AP
    Curr Opin Investig Drugs; 2001 Dec; 2(12):1691-701. PubMed ID: 11892930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective integration of medical and pharmacy claims to better protect patient safety--a long road yet to travel.
    Curtiss FR
    J Manag Care Pharm; 2007 Jun; 13(5):429-30. PubMed ID: 17605515
    [No Abstract]   [Full Text] [Related]  

  • 6. Telithromycin and the FDA: implications for the future.
    Shlaes DM; Moellering RC
    Lancet Infect Dis; 2008 Feb; 8(2):83-5. PubMed ID: 18222155
    [No Abstract]   [Full Text] [Related]  

  • 7. Telithromycin.
    Wellington K; Noble S
    Drugs; 2004; 64(15):1683-94; discussion 1695-6. PubMed ID: 15257629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telithromycin: the first ketolide antimicrobial.
    Nguyen M; Chung EP
    Clin Ther; 2005 Aug; 27(8):1144-63. PubMed ID: 16199242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dalfampridine prior authorization program: a cohort study.
    Gleason PP; Phillips J; Fenrick BA; Delgado-Riley A; Starner CI
    J Manag Care Pharm; 2013; 19(1):18-25. PubMed ID: 23383704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hospitalization rates among patients with community-acquired pneumonia treated with telithromycin vs clarithromycin: results from two randomized, double-blind, clinical trials.
    Niederman MS; Chang JR; Stewart J; Asche CV; Lavin B; Nusrat R; Sullivan SD
    Curr Med Res Opin; 2004 Jul; 20(7):969-80. PubMed ID: 15265241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of cethromycin, a new ketolide, for treatment of community-acquired respiratory infections.
    Hammerschlag MR; Sharma R
    Expert Opin Investig Drugs; 2008 Mar; 17(3):387-400. PubMed ID: 18321237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefit-risk assessment of telithromycin in the treatment of community-acquired pneumonia.
    Brown SD
    Drug Saf; 2008; 31(7):561-75. PubMed ID: 18558790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The wobbly status of ketolides: where do we stand?
    Georgopapadakou NH
    Expert Opin Investig Drugs; 2014 Oct; 23(10):1313-9. PubMed ID: 25154307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults.
    Mathers Dunbar L; Hassman J; Tellier G
    Clin Ther; 2004 Jan; 26(1):48-62. PubMed ID: 14996517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review.
    Clay KD; Hanson JS; Pope SD; Rissmiller RW; Purdum PP; Banks PM
    Ann Intern Med; 2006 Mar; 144(6):415-20. PubMed ID: 16481451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telithromycin new product overview.
    File TM
    J Allergy Clin Immunol; 2005 Feb; 115(2):S1-13. PubMed ID: 15696068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telithromycin in lower respiratory tract infections.
    Blasi F; Cazzola M; Tarsia P; Aliberti S; Baldessari C; Valenti V
    Future Microbiol; 2006 Jun; 1(1):7-16. PubMed ID: 17661681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the regulatory hurdles for antibacterial drug development in the post-Ketek world.
    Echols RM
    Ann N Y Acad Sci; 2011 Dec; 1241():153-61. PubMed ID: 22191531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of telithromycin: application to dosing in the treatment of community-acquired respiratory tract infections.
    Ciervo CA; Shi J
    Curr Med Res Opin; 2005 Oct; 21(10):1641-50. PubMed ID: 16238904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia.
    Tellier G; Niederman MS; Nusrat R; Patel M; Lavin B
    J Antimicrob Chemother; 2004 Aug; 54(2):515-23. PubMed ID: 15269191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.